ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Takeda drug candidates go to new firm

by Jean-François Tremblay
March 20, 2017 | APPEARED IN VOLUME 95, ISSUE 12

Takeda Pharmaceutical will inject eight drug candidates into a new biotech venture, Scohia Pharma. Innovation Network Corp. of Japan, a venture capital fund partly financed by the Japanese government, will own about 70% of the venture; the rest will be held by Takeda and its subsidiary Medipal Holdings. The drug candidates are in the renal, metabolic, and cardiovascular areas. The partners expect the spin-off to conduct research more efficiently while benefiting from Takeda scientists’ input.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment